[
  {
    "ts": null,
    "headline": "Will Librexia ACS Study Setback Dent BMY's Cardiovascular Portfolio?",
    "summary": "BMY ends its Librexia ACS study after an interim review shows milvexian is unlikely to meet goals, while other late-stage studies continue.",
    "url": "https://finnhub.io/api/news?id=79cb6c8e54c3a18c89342c6dd2cd780fcf49c21e607953c6a149216bfd5d1b67",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1763662200,
      "headline": "Will Librexia ACS Study Setback Dent BMY's Cardiovascular Portfolio?",
      "id": 137566502,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BMY",
      "source": "Yahoo",
      "summary": "BMY ends its Librexia ACS study after an interim review shows milvexian is unlikely to meet goals, while other late-stage studies continue.",
      "url": "https://finnhub.io/api/news?id=79cb6c8e54c3a18c89342c6dd2cd780fcf49c21e607953c6a149216bfd5d1b67"
    }
  },
  {
    "ts": null,
    "headline": "The Tech Rotation Is On and Dividend-Paying Blue-Chips Are the Winners",
    "summary": "These six top blue-chip dividend stocks remain outstanding ideas for investors seeking to move away from tech stocks.",
    "url": "https://finnhub.io/api/news?id=ad5f169aaabb4299989bf8db8983462a2cf94703bb592bc7adb78fef97575e4c",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1763648395,
      "headline": "The Tech Rotation Is On and Dividend-Paying Blue-Chips Are the Winners",
      "id": 137556238,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BMY",
      "source": "Yahoo",
      "summary": "These six top blue-chip dividend stocks remain outstanding ideas for investors seeking to move away from tech stocks.",
      "url": "https://finnhub.io/api/news?id=ad5f169aaabb4299989bf8db8983462a2cf94703bb592bc7adb78fef97575e4c"
    }
  },
  {
    "ts": null,
    "headline": "Bristol Myers Squibb Company (BMY) Slipped due to Lowered EPS Guidance",
    "summary": "Cullen Capital Management, LLC, operating under the name Schafer Cullen Capital Management, Inc. (SCCM), has released its “SCCM Value Equity Strategy” third-quarter investor letter. A copy of the letter can be downloaded here. The US equity market continued the rally in the third quarter, with the S&P 500 returning 8.1% and the Russell 1000 Value surging 5.3%. […]",
    "url": "https://finnhub.io/api/news?id=224e2dc7c1ea8bd650b8f443f936dcca37175d1d101a1232e6c106b11b92ac05",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1763644321,
      "headline": "Bristol Myers Squibb Company (BMY) Slipped due to Lowered EPS Guidance",
      "id": 137556647,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BMY",
      "source": "Yahoo",
      "summary": "Cullen Capital Management, LLC, operating under the name Schafer Cullen Capital Management, Inc. (SCCM), has released its “SCCM Value Equity Strategy” third-quarter investor letter. A copy of the letter can be downloaded here. The US equity market continued the rally in the third quarter, with the S&P 500 returning 8.1% and the Russell 1000 Value surging 5.3%. […]",
      "url": "https://finnhub.io/api/news?id=224e2dc7c1ea8bd650b8f443f936dcca37175d1d101a1232e6c106b11b92ac05"
    }
  },
  {
    "ts": null,
    "headline": "Fighting Cancer With 'Smart Bombs.' What New Treatments Mean For Wall Street.",
    "summary": "Targeted chemotherapy is here. So-called antibody drug conjugates could flip the toxic paradigm on its ear, helping more patients.",
    "url": "https://finnhub.io/api/news?id=b8a3aecd9b654a7d44551c2604c3f702f4d949c1fadcc14bcd574f85db55374b",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1763643652,
      "headline": "Fighting Cancer With 'Smart Bombs.' What New Treatments Mean For Wall Street.",
      "id": 137556388,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BMY",
      "source": "Yahoo",
      "summary": "Targeted chemotherapy is here. So-called antibody drug conjugates could flip the toxic paradigm on its ear, helping more patients.",
      "url": "https://finnhub.io/api/news?id=b8a3aecd9b654a7d44551c2604c3f702f4d949c1fadcc14bcd574f85db55374b"
    }
  },
  {
    "ts": null,
    "headline": "This Drugmaker Is Too Cheap to Ignore. Why Bristol Is a Buy.",
    "summary": "For Big Pharma, the triumph of developing a new lifesaving blockbuster drug that generates billions in revenue is inevitably followed by the reality that drug patents have an expiration date.  It’s a challenge that  Bristol Myers Squibb  is navigating in real time as it faces a sharp drop in sales of Revlimid, a leading treatment for multiple myeloma that lost patent protection in 2022.  Other flagship products approaching their loss of exclusivity in 2028 include Eliquis, a blood thinner, and the intravenous formulation of the cancer immunotherapy Opdivo.",
    "url": "https://finnhub.io/api/news?id=095930a75826d0aee56911bca29526d07044581e6ef8d98e8f635a494a0c3c96",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1763643600,
      "headline": "This Drugmaker Is Too Cheap to Ignore. Why Bristol Is a Buy.",
      "id": 137556460,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BMY",
      "source": "Yahoo",
      "summary": "For Big Pharma, the triumph of developing a new lifesaving blockbuster drug that generates billions in revenue is inevitably followed by the reality that drug patents have an expiration date.  It’s a challenge that  Bristol Myers Squibb  is navigating in real time as it faces a sharp drop in sales of Revlimid, a leading treatment for multiple myeloma that lost patent protection in 2022.  Other flagship products approaching their loss of exclusivity in 2028 include Eliquis, a blood thinner, and the intravenous formulation of the cancer immunotherapy Opdivo.",
      "url": "https://finnhub.io/api/news?id=095930a75826d0aee56911bca29526d07044581e6ef8d98e8f635a494a0c3c96"
    }
  },
  {
    "ts": null,
    "headline": "$100,000 In The S&P 500's 5 Cheapest Healthcare Stocks, 4% Average Dividend Yield",
    "summary": "Discover 5 undervalued large-cap health care stocks using a proven screening method.",
    "url": "https://finnhub.io/api/news?id=d057abb57ab8f45949785205029293c9073aa0bb6830b40b53701c1728a2537a",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1763637427,
      "headline": "$100,000 In The S&P 500's 5 Cheapest Healthcare Stocks, 4% Average Dividend Yield",
      "id": 137557117,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1487494602/image_1487494602.jpg?io=getty-c-w1536",
      "related": "BMY",
      "source": "SeekingAlpha",
      "summary": "Discover 5 undervalued large-cap health care stocks using a proven screening method.",
      "url": "https://finnhub.io/api/news?id=d057abb57ab8f45949785205029293c9073aa0bb6830b40b53701c1728a2537a"
    }
  }
]